Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Dec. 2025,
Zhejiang Taimei Medical Technology Co paid€0.00 Mil more to buy back shares than it received from issuing new shares.
It received€5.82 Mil from issuing more debt.
It paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received€0.00 Mil from paying cash dividends to shareholders.
It spent€0.11 Mil on other financial activities.
In all, Zhejiang Taimei Medical Technology Coearned€5.71 Mil on financial activities for the
six
months ended in Dec. 2025.
Zhejiang Taimei Medical Technology Co (FRA:A2V) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Zhejiang Taimei Medical Technology Co's issuance of stock for the
six
months ended in Dec. 2025 was €0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Zhejiang Taimei Medical Technology Co's repurchase of stock for the
six
months ended in Dec. 2025 was €0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Zhejiang Taimei Medical Technology Co's net issuance of debt for the
six
months ended in Dec. 2025 was €5.82 Mil.
Zhejiang Taimei Medical Technology Co received€5.82 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Zhejiang Taimei Medical Technology Co's net issuance of preferred for the
six
months ended in Dec. 2025 was €0.00 Mil.
Zhejiang Taimei Medical Technology Co paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Zhejiang Taimei Medical Technology Co's cash flow for dividends for the
six
months ended in Dec. 2025 was €0.00 Mil.
Zhejiang Taimei Medical Technology Co received€0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Zhejiang Taimei Medical Technology Co's other financing for the
six
months ended in Dec. 2025 was €-0.11 Mil.
Zhejiang Taimei Medical Technology Co spent€0.11 Mil on other financial activities.
Zhejiang Taimei Medical Technology Co Cash Flow from Financing Related Terms
Zhejiang Taimei Medical Technology Co Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Taimei Medical Technology Co Cash Flow from Financing Chart
Zhejiang Taimei Medical Technology Co Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
Cash Flow from Financing
-5.57
38.67
-5.05
36.86
3.02
Zhejiang Taimei Medical Technology Co Semi-Annual Data
Zhejiang Taimei Medical Technology Co Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €3.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of €3.03 Mil mean?
Zhejiang Taimei Medical Technology Co (FRA:A2V) has a Cash Flow from Financing of €3.03 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Zhejiang Taimei Medical Technology Co and its competitors.
Is Zhejiang Taimei Medical Technology Co's Cash Flow from Financing too high?
Zhejiang Taimei Medical Technology Co's current Cash Flow from Financing is €3.03 Mil. Overall, Zhejiang Taimei Medical Technology Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Taimei Medical Technology Co's Cash Flow from Financing compare to VEEV and BTSG?
Zhejiang Taimei Medical Technology Co's Cash Flow from Financing of €3.03 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Healthcare Providers & Services company?
A good Cash Flow from Financing depends on the Healthcare Providers & Services industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Zhejiang Taimei Medical Technology Co and its competitors. Zhejiang Taimei Medical Technology Co's current Cash Flow from Financing is €3.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Taimei Medical Technology Co stock overvalued right now?
Zhejiang Taimei Medical Technology Co (FRA:A2V) has a current Cash Flow from Financing of €3.03 Mil. The current Cash Flow from Financing is €3.03 Mil. Zhejiang Taimei Medical Technology Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Zhejiang Taimei Medical Technology Co (FRA:A2V), the current Cash Flow from Financing is €3.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zhejiang Taimei Medical Technology Co Ltd is a digital solution provider focused on the pharmaceutical and medical device industry in China. It designs and delivers industry-specific software and digital services that facilitate research and development (R&D) and the commercialization of pharmaceuticals and medical devices. The software it offers is cloud-based, allowing users to access it from various devices at any time over the internet, without the need for software installation and maintenance on their devices. It has a geographical presence in Mainland China, the United States, Singapore, Korea, and Others.
11GF Score
Get the complete analysis for FRA:A2V
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A2V has been successfully added to your 
